Literature DB >> 25550957

Acetazolamide pre-treatment before ascending to high altitudes: when to start?

Martin Burtscher1, Hannes Gatterer1, Martin Faulhaber1, Johannes Burtscher2.   

Abstract

Hypoxia is the main responsible factor initiating the symptoms of acute mountain sickness (AMS) in susceptible individuals. Measures that improve oxygenation and/or hasten acclimatization like pre-treatment with acetazolamide will prevent the development of AMS. We hypothesized that pre-treatment with acetazolamide the day before arrival at high altitude would elicit improved oxygenation compared to placebo not until the second day of high-altitude exposure. Fifteen study participants were randomly assigned in a double blind fashion to receive placebo or acetazolamide (2 × 125 mg) before (10 hours and 1 hour) exposure to high altitude (Monte Rosa plateau, 3480 m). Beside AMS scoring, heart rate, minute ventilation, and blood gas analyses were performed during rest and submaximal exercise at low altitude and on day 1, 2 and 3 at high altitude. From low altitude to day 1 at high altitude changes of pH (7.41 ± 0.01 vs. 7.48 ± 0.04) and HCO3 (24.0 ± 0.46 vs. 24.6 ± 2.6 mmol/L) within the placebo group differed significantly from those within the acetazolamide group (7.41 ± 0.01 vs. 7.41 ± 0.02; 23.6 ± 0.38 vs. 20.7 ± 1.8 mmol/L) (P < 0.05). AMS incidence tended to be lower with acetazolamide (P < 0.1). From low altitude to day 2 at high altitude changes of paO2 within the placebo group (75.3 ± 5.4 vs. 40.5 ± 3.4 mmHg) differed significantly from those within the acetazolamide group (76.5 ± 4.5 vs. 48.2 ± 4.9 mmHg) (P < 0.05). In conclusion, pre-treatment with low-dose acetazolamide on the day before ascending to high altitude tended to reduce AMS incidence on the first day at high altitude but improved oxygen availability to tissues not until the second day of exposure. Therefore, it is suggested that the beginning of pre-treatment with low-dose acetazolamide at least two days before arrival at high altitude, in contrast to usual recommendations, would be of greater beneficial effect on AMS development.

Entities:  

Keywords:  Acute mountain sickness; low-dose acetazolamide; pre-treatment; prevention

Year:  2014        PMID: 25550957      PMCID: PMC4276215     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  21 in total

1.  Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial.

Authors:  Buddha Basnyat; Jeffrey H Gertsch; E William Johnson; Franco Castro-Marin; Yoshio Inoue; Clement Yeh
Journal:  High Alt Med Biol       Date:  2003       Impact factor: 1.981

2.  Cognitive changes at high altitude in healthy climbers and in climbers developing acute mountain sickness.

Authors:  M Regard; T Landis; J Casey; M Maggiorini; P Bärtsch; O Oelz
Journal:  Aviat Space Environ Med       Date:  1991-04

Review 3.  Hypoxia-related altitude illnesses.

Authors:  Nikolaus Netzer; Kingman Strohl; Martin Faulhaber; Hannes Gatterer; Martin Burtscher
Journal:  J Travel Med       Date:  2013-03-11       Impact factor: 8.490

4.  Prevalence of acute mountain sickness in the Eastern Alps.

Authors:  Klemens Mairer; Maria Wille; Thomas Bucher; Martin Burtscher
Journal:  High Alt Med Biol       Date:  2009       Impact factor: 1.981

5.  Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial.

Authors:  M Burtscher; R Likar; W Nachbauer; M Philadelphy
Journal:  BMJ       Date:  1998-04-04

6.  Effect of acetazolamide on pulmonary and muscle gas exchange during normoxic and hypoxic exercise.

Authors:  Amy M Jonk; Irene P van den Berg; I Mark Olfert; D Walter Wray; Tatsuya Arai; Susan R Hopkins; Peter D Wagner
Journal:  J Physiol       Date:  2007-01-11       Impact factor: 5.182

Review 7.  Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness.

Authors:  David E Leaf; David S Goldfarb
Journal:  J Appl Physiol (1985)       Date:  2006-10-05

8.  Psychophysical bases of perceived exertion.

Authors:  G A Borg
Journal:  Med Sci Sports Exerc       Date:  1982       Impact factor: 5.411

9.  Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial.

Authors:  Buddha Basnyat; Jeffrey H Gertsch; Peter S Holck; E William Johnson; Andrew M Luks; Benjamin P Donham; Ross J Fleischman; Daniel W Gowder; Jason S Hawksworth; Brett T Jensen; Richard J Kleiman; Adam H Loveridge; Elizabeth B Lundeen; Sheri L Newman; Jesse A Noboa; Daniel P Miegs; Kenneth A O'Beirne; Kelly B Philpot; Miriam N Schultz; Matthew C Valente; Mandie R Wiebers; Erik R Swenson
Journal:  High Alt Med Biol       Date:  2006       Impact factor: 1.981

10.  Effects of respiratory alkalosis on human skeletal muscle metabolism at the onset of submaximal exercise.

Authors:  P J LeBlanc; M L Parolin; N L Jones; G J F Heigenhauser
Journal:  J Physiol       Date:  2002-10-01       Impact factor: 5.182

View more
  8 in total

1.  Diagnosis and prediction of the occurrence of acute mountain sickness measuring oxygen saturation--independent of absolute altitude?

Authors:  Veronika Leichtfried; Daniel Basic; Martin Burtscher; Raffaella Matteucci Gothe; Uwe Siebert; Wolfgang Schobersberger
Journal:  Sleep Breath       Date:  2015-06-02       Impact factor: 2.816

Review 2.  Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.

Authors:  Víctor H Nieto Estrada; Daniel Molano Franco; Roger David Medina; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2017-06-27

3.  Toward the Discovery of a Novel Class of Leads for High Altitude Disorders by Virtual Screening and Molecular Dynamics Approaches Targeting Carbonic Anhydrase.

Authors:  Amena Ali; Abuzer Ali; Musarrat Husain Warsi; Mohammad Akhlaquer Rahman; Mohamed Jawed Ahsan; Faizul Azam
Journal:  Int J Mol Sci       Date:  2022-05-02       Impact factor: 6.208

4.  Carbonic anhydrase inhibition improves pulmonary artery reactivity and nitric oxide-mediated relaxation in sugen-hypoxia model of pulmonary hypertension.

Authors:  Helen Christou; Zoe Michael; Fotios Spyropoulos; Yunfei Chen; Dan Rong; Raouf A Khalil
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-04-07       Impact factor: 3.210

Review 5.  The Use of Pulse Oximetry in the Assessment of Acclimatization to High Altitude.

Authors:  Tobias Dünnwald; Roland Kienast; David Niederseer; Martin Burtscher
Journal:  Sensors (Basel)       Date:  2021-02-10       Impact factor: 3.576

Review 6.  High-altitude illnesses: Old stories and new insights into the pathophysiology, treatment and prevention.

Authors:  Martin Burtscher; Urs Hefti; Jacqueline Pichler Hefti
Journal:  Sports Med Health Sci       Date:  2021-04-16

7.  Acute Mountain Sickness Symptom Severity at the South Pole: The Influence of Self-Selected Prophylaxis with Acetazolamide.

Authors:  Michael F Harrison; Paul J Anderson; Jacob B Johnson; Maile Richert; Andrew D Miller; Bruce D Johnson
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

8.  Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study.

Authors:  Arthur R Bradwell; Kimberley Ashdown; Carla Rue; John Delamere; Owen D Thomas; Samuel J E Lucas; Alex D Wright; Stephen J Harris; Stephen D Myers
Journal:  BMJ Open Sport Exerc Med       Date:  2018-01-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.